NOX
vs
S
S&P/ASX 300
NOX
Over the past 12 months, NOX has underperformed S&P/ASX 300, delivering a return of -16% compared to the S&P/ASX 300's +5% growth.
Stocks Performance
NOX vs S&P/ASX 300
Performance Gap
NOX vs S&P/ASX 300
Performance By Year
NOX vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Noxopharm Ltd
Glance View
Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Gordon, New South Wales. The company went IPO on 2016-08-09. The firm is focused on the treatment of cancer and cytokine release syndrome or septic shock. The firm is engaged in the drug development program, which focuses on the treatment of pancreatic cancer and glioblastoma. The firm's lead drug candidate is called Veyonda (NOX66), which is a therapy developed for chemotherapy and radiotherapy in the treatment of late-stage cancers. Its drug candidate is in Phase II clinical trials. The firm's four pillar oncology program include externally delivered radiation (DARRT) Internally delivered radiation (LuPIN), Checkpoint inhibitors (IONIC) and Chemotherapy (CEP).
